Addex Therapeutics Ltd ADXN · Stock Open Addex Therapeutics Ltd in new tab
Addex Therapeutics Ltd Analysis (ADXN)
Is Addex Therapeutics Ltd a good investment? Addex Therapeutics Ltd (ADXN) is currently trading at 5.79 USD.
Earnings Schedule: Addex Therapeutics Ltd is expected to release its next earnings report on Aug. 24, 2026. The market consensus estimate for Forward EPS is -0.05.
Investor FAQ
Does Addex Therapeutics Ltd pay a dividend?
No, it does not currently pay a dividend.
What asset class is Addex Therapeutics Ltd?
Addex Therapeutics Ltd is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 24, 2026. The company currently has a trailing EPS of -8.90.
Company Profile
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-induced dyskinesia. The company also develops ADX71149, which is in phase 1 for undisclosed indication; and GABAB PAM for the treatment pain, anxiety, addiction, chronic cough, and overactive bladder. It has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the develop mGlu2 PAM compounds for the treatment of human health; and license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
| Split Date | Split Ratio to 1 |
|---|---|
| Oct. 23, 2023 | 0.050000 |
Community Discussion